Most of the early coverage on the Medicare GLP-1 Bridge zeroed in on one number: $50 a month. That’s real, and for many Medicare beneficiaries who’ve been paying hundreds out of pocket for Wegovy or Zepbound, it’s genuinely significant. But the program that launched July 1, 2026 is more complicated than that headline suggests, and the complications matter right now, before beneficiaries and their doctors get tripped up by them.

Here’s what’s actually happening, and what you need to know if you’re considering enrolling or already taking one of these medications.

The Program Is Real, But It Has an Expiration Date

The Medicare GLP-1 Bridge is a CMS (Centers for Medicare & Medicaid Services) demonstration program, not a permanent benefit. It runs from July 1, 2026 through December 31, 2027, and covers three specific medications for weight loss: Wegovy (all formulations), Zepbound (KwikPen only, not the vials), and Foundayo. The $50/month copay applies across the board, regardless of which drug or dose you’re on.

Eighteen months sounds like a decent runway. The problem is what comes after. CMS had originally planned a follow-on program called the BALANCE Model, which would have embedded GLP-1 obesity coverage permanently into Part D drug plans starting in 2027. That model has been delayed indefinitely. There’s currently no guaranteed coverage pathway once the Bridge ends December 31, 2027. If you start therapy now and respond well, you’ll be facing a coverage cliff in a year and a half with no clear landing spot. That’s not a reason to skip the program, but it’s absolutely something to factor into your planning, especially if you’re discussing long-term treatment with your doctor.

The BMI Rules Are More Forgiving Than You Think

Recommended OMRON Bronze Upper Arm Blood Pressure Monitor

Stores unlimited readings via app, clinically validated for accurate home blood pressure monitoring.

Check Price →
BMI ThresholdAdditional Conditions RequiredCoverage Status
35 or aboveNoneEligible
30 or aboveHeart failure, uncontrolled hypertension, or chronic kidney diseaseEligible
27 or abovePre-diabetes, prior heart attack or stroke, or peripheral artery diseaseEligible

Helpful resource: OMRON Platinum Blood Pressure Monitor Upper Arm is a top-rated option for this. (As an Amazon Associate this site earns from qualifying purchases.)

Eligibility is structured around three clinical tiers, and the threshold most people assume applies, BMI of 35 or higher, is actually just the broadest one. You may qualify at a lower BMI depending on your health history.

The three tiers work like this: BMI 35 or above qualifies on its own, no additional conditions required. BMI 30 or above qualifies if you also have heart failure, uncontrolled hypertension, or chronic kidney disease. BMI 27 or above qualifies if you have pre-diabetes, a prior heart attack or stroke, or peripheral artery disease. That third tier captures a meaningful number of people who might assume they don’t qualify.

There’s also a critical nuance that’s easy to miss: CMS measures BMI at the time you first started GLP-1 therapy, not at the time you enroll in the Bridge. If you’ve been on semaglutide for six months and have already lost 30 pounds, dropping your BMI below the qualifying threshold, you’re still eligible as long as you met the threshold when your prescription began. The Medicare Rights Center flagged this specifically in their June 2026 coverage, noting that beneficiaries already on GLP-1 therapy shouldn’t assume they’ve aged out of eligibility because the scale has moved. Bring documentation of your starting weight and BMI to your next appointment.

The $50 Copay Has Fine Print That Could Sting You

The $50 monthly copay is straightforward until you look at how it interacts with the rest of your Part D drug coverage. Three things that don’t apply here that normally would:

First, the $50 does not count toward your Part D deductible. You’ll still owe your full deductible on other medications covered through your plan.

Second, it doesn’t count toward your annual out-of-pocket cap under Part D. In 2026, that cap is $2,000, and GLP-1 Bridge copays won’t help you reach it faster.

Third, Extra Help, formally called the Low Income Subsidy, cannot be applied to Bridge claims. If you’re a lower-income beneficiary who normally gets cost-sharing assistance through Extra Help, you don’t get that help here. You pay $50 like everyone else. Manufacturer coupons and discount programs like GoodRx are also excluded.

For most people, $50 a month is still dramatically better than list price. But for beneficiaries on tight fixed incomes who rely on Extra Help for other medications, this is worth a hard look before enrolling.

Your Doctor’s Office May Not Know How Prior Authorization Works Here

This is where the real-world friction is showing up. Prior authorizations for the Bridge are not processed through your own Part D insurance plan. They go through a CMS-designated central processor, which is Humana, regardless of who your Part D insurer is. Your doctor’s billing staff may have sent the prior auth request to your usual plan and heard nothing back, or gotten a denial, because the request went to the wrong place entirely.

According to CMS’s provider guidance, prescribers need to submit prior authorization requests directly to the Bridge processor, not their patient’s Part D plan. This workflow is catching prescribers off guard across the country. If your prescription has been held up or denied, it’s worth asking your doctor’s office specifically whether they submitted to Humana’s Bridge processor or to your regular Part D plan. A misdirected prior auth is fixable; it just adds delay.

The prior authorization process is also retrospective, meaning it can be applied to GLP-1 therapy already in progress, which is relevant for anyone who started these medications before July 1 and is now trying to bring their costs down through the Bridge.

What to Do Right Now

If you’re already taking Wegovy, Zepbound’s KwikPen, or Foundayo for weight loss, contact your prescriber this week and ask whether they’ve initiated Bridge enrollment on your behalf. Don’t assume it’s automatic.

If you’re considering starting one of these medications, talk with your doctor about which tier applies to you and gather documentation of your BMI and relevant conditions. The eligibility criteria are specific enough that a prescriber’s notes matter, and a formal prior authorization built on accurate records is easier to process than one that has to be corrected later.

This program is a genuine opportunity for the right patients, and the 18-month window is live now. But the fine print around cost-sharing, prior authorization routing, and the post-2027 coverage gap means the decisions you make in the next few months deserve more than a quick call to your pharmacy. Talk with your doctor, and consider reaching out to a licensed Medicare counselor through your State Health Insurance Assistance Program (SHIP), which offers free, unbiased help. You can find your local SHIP contact at Medicare.gov.

Sources

This article is for informational purposes only. Medicare rules change annually. Always verify current plan details at Medicare.gov or by calling 1-800-MEDICARE (1-800-633-4227). This site does not sell insurance or recommend specific plans.

Disclosure: As an Amazon Associate, we earn a small commission from qualifying purchases at no extra cost to you. We only recommend products that genuinely support the topics covered in this article.

  • Medicare For Dummies (~$22), The definitive consumer guide to Medicare, enrollment windows, Part A/B/C/D, and supplement plans.
  • Get What’s Yours for Medicare (~$17), Maximize your Medicare benefits and minimize out-of-pocket costs. Covers Part D drug coverage gaps and Medigap in depth.